Who are Anti-IL12/23 or anti-IL23 - Ustekinumab's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Ustekinumab (UST), BMS-986165, Ustekinumab Injection, Ustekinumab IV, Ustekinumab SC, Stelara (ustekinumab).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/anti-il12-23-or-anti-il23-ustekinumab.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Anti-IL12/23 or anti-IL23 - Ustekinumab — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Anti-IL12/23 or anti-IL23 - Ustekinumab (Anti-IL12/23 or anti-IL23 - Ustekinumab) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Monoclonal antibody; IL-12/IL-23 inhibitor. Area: Immunology.

marketed Monoclonal antibody; IL-12/IL-23 inhibitor IL-12 p40 subunit (shared with IL-23) Immunology Biologic Live · refreshed every 30 min

Target snapshot

Anti-IL12/23 or anti-IL23 - Ustekinumab (Anti-IL12/23 or anti-IL23 - Ustekinumab) — University of Calgary. Ustekinumab is a monoclonal antibody that blocks the IL-12 and IL-23 cytokines, which are key drivers of inflammatory and autoimmune responses.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Anti-IL12/23 or anti-IL23 - Ustekinumab TARGET	Anti-IL12/23 or anti-IL23 - Ustekinumab	University of Calgary	marketed	Monoclonal antibody; IL-12/IL-23 inhibitor	IL-12 p40 subunit (shared with IL-23)
Ustekinumab (UST)	Ustekinumab (UST)	Second Affiliated Hospital, School of Medicine, Zhejiang University	marketed	IL-12/IL-23 inhibitor monoclonal antibody	IL-12 p40 / IL-23 p40 subunit
BMS-986165	BMS-986165	Bristol-Myers Squibb	marketed	IL-12/IL-23 inhibitor	IL-12/IL-23 p40 subunit
Ustekinumab Injection	Ustekinumab Injection	National Medical Research Center for Children's Health, Russian Federation	marketed	IL-12/IL-23 inhibitor (monoclonal antibody)	IL-12/IL-23 p40 subunit
Ustekinumab IV	Ustekinumab IV	Janssen Research & Development, LLC	phase 3	IL-12/IL-23 inhibitor (monoclonal antibody)	IL-12 p40 subunit / IL-23 p40 subunit
Ustekinumab SC	Ustekinumab SC	Janssen Research & Development, LLC	phase 3	IL-12/IL-23 inhibitor monoclonal antibody	IL-12/IL-23 p40 subunit
Stelara (ustekinumab)	Stelara (ustekinumab)	National Institute of Allergy and Infectious Diseases (NIAID)	phase 3	IL-12/IL-23 inhibitor (monoclonal antibody)	IL-12 p40 subunit / IL-23 p40 subunit

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Monoclonal antibody; IL-12/IL-23 inhibitor class)

University of Calgary · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Anti-IL12/23 or anti-IL23 - Ustekinumab — Competitive Intelligence Brief. https://druglandscape.com/ci/anti-il12-23-or-anti-il23-ustekinumab. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab